Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Identification of Two Protein-Signaling States Delineating Transcriptionally Heterogeneous Human Medulloblastoma.

Zomerman WW, Plasschaert SLA, Conroy S, Scherpen FJ, Meeuwsen-de Boer TGJ, Lourens HJ, Guerrero Llobet S, Smit MJ, Slagter-Menkema L, Seitz A, Gidding CEM, Hulleman E, Wesseling P, Meijer L, van Kempen LC, van den Berg A, Warmerdam DO, Kruyt FAE, Foijer F, van Vugt MATM, den Dunnen WFA, Hoving EW, Guryev V, de Bont ESJM, Bruggeman SWM.

Cell Rep. 2018 Mar 20;22(12):3206-3216. doi: 10.1016/j.celrep.2018.02.089.

2.

Peptide microarray profiling identifies phospholipase C gamma 1 (PLC-γ1) as a potential target for t(8;21) AML.

Mahmud H, Scherpen FJG, de Boer TM, Lourens HJ, Schoenherr C, Eder M, Scherr M, Guryev V, De Bont ES.

Oncotarget. 2017 Jun 27;8(40):67344-67354. doi: 10.18632/oncotarget.18631. eCollection 2017 Sep 15.

3.

Epidermal growth factor receptor is expressed and active in a subset of acute myeloid leukemia.

Mahmud H, Kornblau SM, Ter Elst A, Scherpen FJ, Qiu YH, Coombes KR, de Bont ES.

J Hematol Oncol. 2016 Aug 3;9(1):64. doi: 10.1186/s13045-016-0294-x.

4.

Effect of IKZF1 deletions on signal transduction pathways in Philadelphia chromosome negative pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL).

van der Sligte NE, Scherpen FJ, Ter Elst A, Guryev V, van Leeuwen FN, de Bont ES.

Exp Hematol Oncol. 2015 Aug 12;4:23. doi: 10.1186/s40164-015-0017-y. eCollection 2015.

5.

Essential role for cyclic-AMP responsive element binding protein 1 (CREB) in the survival of acute lymphoblastic leukemia.

van der Sligte NE, Kampen KR, ter Elst A, Scherpen FJ, Meeuwsen-de Boer TG, Guryev V, van Leeuwen FN, Kornblau SM, de Bont ES.

Oncotarget. 2015 Jun 20;6(17):14970-81.

6.

EphB1 Suppression in Acute Myelogenous Leukemia: Regulating the DNA Damage Control System.

Kampen KR, Scherpen FJ, Garcia-Manero G, Yang H, Kaspers GJ, Cloos J, Zwaan CM, van den Heuvel-Eibrink MM, Kornblau SM, De Bont ES.

Mol Cancer Res. 2015 Jun;13(6):982-92. doi: 10.1158/1541-7786.MCR-14-0660-T. Epub 2015 May 5.

7.

Growth-factor-driven rescue to receptor tyrosine kinase (RTK) inhibitors through Akt and Erk phosphorylation in pediatric low grade astrocytoma and ependymoma.

Sie M, den Dunnen WF, Lourens HJ, Meeuwsen-de Boer TG, Scherpen FJ, Zomerman WW, Kampen KR, Hoving EW, de Bont ES.

PLoS One. 2015 Mar 23;10(3):e0122555. doi: 10.1371/journal.pone.0122555. eCollection 2015.

8.

Kinase activity profiling reveals active signal transduction pathways in pediatric acute lymphoblastic leukemia: a new approach for target discovery.

van der Sligte NE, Scherpen FJ, Meeuwsen-de Boer TG, Lourens HJ, Ter Elst A, Diks SH, Guryev V, Peppelenbosch MP, van Leeuwen FN, de Bont ES.

Proteomics. 2015 Apr;15(7):1245-54. doi: 10.1002/pmic.201400286. Epub 2015 Jan 21.

PMID:
25422122
9.

Insights in dynamic kinome reprogramming as a consequence of MEK inhibition in MLL-rearranged AML.

Kampen KR, Ter Elst A, Mahmud H, Scherpen FJ, Diks SH, Peppelenbosch MP, de Haas V, Guryev V, de Bont ES.

Leukemia. 2014 Mar;28(3):589-99. doi: 10.1038/leu.2013.342. Epub 2013 Nov 18.

PMID:
24240200
10.

EphB2 activity plays a pivotal role in pediatric medulloblastoma cell adhesion and invasion.

Sikkema AH, den Dunnen WF, Hulleman E, van Vuurden DG, Garcia-Manero G, Yang H, Scherpen FJ, Kampen KR, Hoving EW, Kamps WA, Diks SH, Peppelenbosch MP, de Bont ES.

Neuro Oncol. 2012 Sep;14(9):1125-35. doi: 10.1093/neuonc/nos130. Epub 2012 Jun 21.

11.

MBL2 and fever during neutropenia in children with acute lymphoblastic leukaemia.

te Poele EM, Siedlinski M, Anne de Pagter PJ, Bierings MB, Scherpen FJ, Meeuwsen-de Boer TG, Koppelman GH, Postma DS, Kamps WA, Boezen HM, de Bont ES.

Br J Haematol. 2012 Apr;157(1):132-5. doi: 10.1111/j.1365-2141.2011.08912.x. Epub 2011 Nov 3. No abstract available.

PMID:
22050689
12.

Stromal interaction essential for vascular endothelial growth factor A-induced tumour growth via transforming growth factor-β signalling.

Weidenaar AC, ter Elst A, Kampen KR, Meeuwsen-de Boer TG, de Jonge HJ, Scherpen FJ, den Dunnen WF, Kamps WA, de Bont ES.

Br J Cancer. 2011 Dec 6;105(12):1856-63. doi: 10.1038/bjc.2011.460. Epub 2011 Nov 1.

13.

Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia.

Ter Elst A, Ma B, Scherpen FJ, de Jonge HJ, Douwes J, Wierenga AT, Schuringa JJ, Kamps WA, de Bont ES.

Cancer Res. 2011 Apr 1;71(7):2761-71. doi: 10.1158/0008-5472.CAN-10-0402. Epub 2011 Mar 29.

14.

Identification of new possible targets for leukemia treatment by kinase activity profiling.

Ter Elst A, Diks SH, Kampen KR, Hoogerbrugge PM, Ruijtenbeek R, Boender PJ, Sikkema AH, Scherpen FJ, Kamps WA, Peppelenbosch MP, de Bont ES.

Leuk Lymphoma. 2011 Jan;52(1):122-30. doi: 10.3109/10428194.2010.535181. Epub 2010 Dec 6.

PMID:
21133721
15.

Tumour vasculature and angiogenic profile of paediatric pilocytic astrocytoma; is it much different from glioblastoma?

Sie M, de Bont ES, Scherpen FJ, Hoving EW, den Dunnen WF.

Neuropathol Appl Neurobiol. 2010 Dec;36(7):636-47. doi: 10.1111/j.1365-2990.2010.01113.x.

PMID:
20704656
16.

VEGF-A promotes lymphoma tumour growth by activation of STAT proteins and inhibition of p27(KIP1) via paracrine mechanisms.

Roorda BD, Ter Elst A, Scherpen FJ, Meeuwsen-de Boer TG, Kamps WA, de Bont ES.

Eur J Cancer. 2010 Mar;46(5):974-82. doi: 10.1016/j.ejca.2009.12.027. Epub 2010 Jan 22.

PMID:
20064707
17.

Kinome profiling in pediatric brain tumors as a new approach for target discovery.

Sikkema AH, Diks SH, den Dunnen WF, ter Elst A, Scherpen FJ, Hoving EW, Ruijtenbeek R, Boender PJ, de Wijn R, Kamps WA, Peppelenbosch MP, de Bont ES.

Cancer Res. 2009 Jul 15;69(14):5987-95. doi: 10.1158/0008-5472.CAN-08-3660. Epub 2009 Jun 30.

18.

Endogenous vascular endothelial growth factor-C expression is associated with decreased drug responsiveness in childhood acute myeloid leukemia.

de Jonge HJ, Weidenaar AC, Ter Elst A, Boezen HM, Scherpen FJ, Bouma-Ter Steege JC, Kaspers GJ, Goemans BF, Creutzig U, Zimmermann M, Kamps WA, de Bont ES.

Clin Cancer Res. 2008 Feb 1;14(3):924-30. doi: 10.1158/1078-0432.CCR-07-1821.

19.

Generation of autologous cytotoxic and helper T-cell responses against the B-cell leukemia-associated antigen HB-1: relevance for precursor B-ALL-specific immunotherapy.

de Rijke B, Fredrix H, Zoetbrood A, Scherpen F, Witteveen H, de Witte T, van de Wiel-Van Kemenade E, Dolstra H.

Blood. 2003 Oct 15;102(8):2885-91. Epub 2003 Jul 3.

20.

Bi-directional allelic recognition of the human minor histocompatibility antigen HB-1 by cytotoxic T lymphocytes.

Dolstra H, de Rijke B, Fredrix H, Balas A, Maas F, Scherpen F, Aviles MJ, Vicario JL, Beekman NJ, Ossendorp F, de Witte TM, van de Wiel-van Kemenade E.

Eur J Immunol. 2002 Oct;32(10):2748-58.

21.

Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients.

de Bont ES, Fidler V, Meeuwsen T, Scherpen F, Hählen K, Kamps WA.

Clin Cancer Res. 2002 Sep;8(9):2856-61.

22.

Mobilized human CD34+ hematopoietic stem cells enhance tumor growth in a nonobese diabetic/severe combined immunodeficient mouse model of human non-Hodgkin's lymphoma.

de Bont ES, Guikema JE, Scherpen F, Meeuwsen T, Kamps WA, Vellenga E, Bos NA.

Cancer Res. 2001 Oct 15;61(20):7654-9.

Supplemental Content

Loading ...
Support Center